A Phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma (Q44244797)

1 December 2017

title

A Phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma (English)

1 reference

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

11 November 2022

main subject

phase II clinical trial

0 references

1 reference

1 reference

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

11 November 2022

author name string

R. Pazdur

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1735078

11 November 2022

J. A. Ajani

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1735078

11 November 2022

R. Winn

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1735078

11 November 2022

J. Bearden

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1735078

11 November 2022

R. J. Belt

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1735078

11 November 2022

S. Pilat

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1735078

11 November 2022

R. Hallinan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1735078

11 November 2022

B. Levin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1735078

11 November 2022

language of work or name

English

0 references

publication date

1 February 1992

1 reference

1 December 2017

15 February 1992

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1735078

full work available at URL

11 November 2022

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

1 reference

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

11 November 2022

1 reference

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

11 November 2022

1 reference

1 December 2017

volume

69

1 reference

1 December 2017

issue

4

1 reference

1 December 2017

page(s)

878-882

1 reference

5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2819920215%2969%3A4%3C878%3A%3AAID-CNCR2820690407%3E3.0.CO%3B2-0

A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas

21 January 2018

3

1 reference

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study

11 November 2022

5

1 reference

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

Randomized study of combination chemotherapy in unresectable gastric cancer. The Gastrointestinal Tumor Study Group

11 November 2022

6

1 reference

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three-arm randomized trial in metastatic gastric cancer. Gastrointestinal Tumor Study Group

11 November 2022

7

1 reference

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer

11 November 2022

8

1 reference

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer

11 November 2022

9

1 reference

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid

11 November 2022

11

1 reference

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma

11 November 2022

13

1 reference

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma

11 November 2022

15

1 reference

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity.

11 November 2022

16

1 reference

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study

11 November 2022

17

1 reference

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma

11 November 2022

20

1 reference

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

Interferon effects upon fluorouracil metabolism by HL-60 cells

11 November 2022

23

1 reference

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

Proceedings of the American Association for Cancer Research

11 November 2022

25

31

402

Wadler

1990

1 reference

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

https://api.crossref.org/works/10.1002/1097-0142(19920215)69:4%3C878::AID-CNCR2820690407%3E3.0.CO;2-0

11 November 2022

Identifiers

10.1002/1097-0142(19920215)69:4<878::AID-CNCR2820690407>3.0.CO;2-0

1 reference

1 December 2017

1 reference